Stratifying Critically Ill Patients for Novel Ferroptosis or Pyroptosis Intervention Strategies

Innovative Cell Death Diagnostics Allowing Stratifying Critically Ill Patients for Novel Ferroptosis or Pyroptosis Intervention Strategies

Status

Recruiting

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06928649

Acronym

ICU-FERRO

Enrollment

600

Registered

2025-04-15

Start date

2024-03-13

Completion date

2026-08-31

Last updated

2025-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis, Subarachnoid Haemorrhage (SAH), Trauma Related Injuries

Brief summary

In order to better determine which therapy is best for patiënts which present with organ falure during the course of their stay in the intesive care unit (ICU) , one has to determine which underlying mechanism is causing this organ falure. We will determine levels of so called biomarkers for ferroptosis (a mechan ism of iron-related cell death) in the peripheral blood and biological fluids of criticaly ill patients admitted to the ICU with a catastrrophy (severe infection, trauma ...) . Why ? If it turns out that this ferroptosis plays a role in the ocurrence of organ failure in the critially ill, this will lead to new therapies in the future as drugs become more and more available which can influene this biochemical pahway. of iron-relatd death.

Interventions

DIAGNOSTIC_TESTBlood sampling

Blood sampling: 3 first days of admision, 2 ml of plasma daily Urine, BALF, CSF sampling: 1 day during 3 first days of admission

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Admitted to the ICU of UZA * Critically ill and predicted to be hospitalised in the ICU for \> 48 hours (i.e. mostly patients admitted for sepsis, trauma, haemorrhagic shock, neurological catastrophe … which means at risk to develop mono-or multiple organ failure) * With arterial line in place (for blood sampling)

Exclusion criteria

* Refusal of consent by patient or closest relative * Postoperative patients after major surgery in whom prolonged ICU stay is not foreseen (i.e. elective cardiac surgery

Design outcomes

Primary

Measure	Time frame	Description
Number of patients with survival after 28 days.	28 days	Survival in and after ICU.

Secondary

Measure	Time frame	Description
Change from baseline concentration of Norepinephrine every day during ICU stay	28 days	—
Change in SOFA score during ICU stay	Change from enrollment to 14 days of ICU stay	SOFA score, with a higher score for more severe organ failure

Countries

Belgium

Contacts

Primary ContactTom Stroobants, MD

tom.stroobants@uza.be+32 3 821 / 24 52

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026